Marker Therapeutics (MRKR) Liabilities from Discontinued Operations (2022 - 2023)

Marker Therapeutics (MRKR) reported Liabilities from Discontinued Operations of 260280.0 for Q2 2023, down 96.3% quarter-over-quarter from 7039338.0 in Q4 2022.

Marker Therapeutics (MRKR) Liabilities from Discontinued Operations (2022 - 2023) Analysis & Trends

Marker Therapeutics (MRKR) has 2 years of Liabilities from Discontinued Operations data on file, last reported at 260280.0 in Q2 2023.

  • Liabilities from Discontinued Operations for Q2 2023 came in at 260280.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2023 was 260280.0 (changed N/A YoY), and the FY2022 annual result was 7039338.0, changed N/A from the prior year.
  • Liabilities from Discontinued Operations slipped to 260280.0 in Q2 2023 per MRKR's latest filing, from 7039338.0 in the prior quarter.
  • Over five years, Liabilities from Discontinued Operations peaked at 7039338.0 in Q4 2022 and troughed at 260280.0 in Q2 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 719,706.53 Bn 719,706.50 Bn -
2 Belite Bio 55,800.00 Bn 55,800.00 Bn -
3 Quantum Biopharma 18,182.30 Bn 18,182.29 Bn -
4 Legend Biotech 3,154.00 Bn 3,153.71 Bn 242.10 Mn
5 Akari Therapeutics 1,844.30 Bn 1,844.29 Bn -
6 Evaxion A 1,567.96 Bn 1,567.94 Bn -
7 Psyence Biomedical 251.43 Bn 251.42 Bn -
8 Vertex Pharmaceuticals 112.56 Bn 105.31 Bn 2.59 Bn
9 Abivax 94.37 Bn 94.37 Bn -
10 Marker Therapeutics 28.20 Mn 28.20 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2023 260,280.00
Jun 30, 2023 260,280.00
Dec 31, 2022 7.04 Mn
Dec 31, 2022 7.04 Mn